isirv Antiviral Group
News Q2 2022
| Q4 / 2022 | Q3 / 2022 | Q2 / 2022 | Q1 / 2022 | 2021 | 2019 | |||||||||
Q2 2022
Neuraminidase Inhibitors
Characterization of influenza B viruses with reduced susceptibility to influenza neuraminidase inhibitors…read more
Frequency and distribution of H1N1 influenza A viruses with oseltamivir-resistant mutations worldwide before and after the 2009 pandemic…read more
Baloxavir Marboxil (Keywords: Influenza baloxavir; baloxavir marboxil)
Pleiotropic Effects of Influenza H1, H3, and B Baloxavir-Resistant Substitutions on Replication, Sensitivity to Baloxavir, and Interferon Expression…read more
Duration of fever and symptoms in influenza-infected children treated with baloxavir marboxil during the 2019-2020 season in Japan and detection of influenza virus with the PA E23K substitution…read more
A novel E198K substitution in the PA gene of influenza A virus with reduced susceptibility to baloxavir acid… read more
New Drug Discovery
Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors… read more
Reviews
Influenza antivirals and animal models…read more
Preclinical and clinical developments for combination treatment of influenza… read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA